The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
 
Tamar Tadmor
Research Funding - MSD (Inst)
 
Toby A. Eyre
Honoraria - Abbvie; AstraZeneca/MedImmune; Autolus Therapeutics; Gilead Sciences; Incyte; Janssen Oncology; Loxo/Lilly; Roche; Secura Bio
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; Incyte; Kite/Gilead; Loxo; Roche; Secura Bio
Research Funding - AstraZeneca/MedImmune; BeiGene
 
Ohad Benjamini
Consulting or Advisory Role - Abbvie; AstraZeneca; Janssen
 
Arvind Chaudhry
Stock and Other Ownership Interests - Immunomedics; Novartis
Research Funding - Abbvie; Arcus Biosciences; AstraZeneca; Bayer; BeiGene; Exelixis; Gilead Sciences; Medlink; Merck; Mersana; Roche
 
Juan Shen
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Siyang Leng
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Mohammed Z.H. Farooqui
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
David Lavie
Consulting or Advisory Role - Abbvie; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Abbvie